Suven Life Sciences
SUVEN · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti Listing date: Oct. 23, 2003 · Employees: 130 · Hyderabad · http://www.suven.com

Stock Price vs Company Growth
1d
0.6%
1w
2.0%
1m
0.2%
3m
22.3%
6m
17.6%
1y
41.2%
5y
16.4%
10y
4.3%
all
8.1%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 117 0.6%
113
169
Company Overview

Sales
8.42 Cr
Growth: -0.7%
Profit after Tax
-146 Cr
Growth: 25.3%
Small Cap
2,561 Cr
P/S: 304.4x
Industry P/S: 3.1x
Fundamentals

Sales (Cr) ₹ 8.42
Growth -0.7%
EBITDA -1892.2%
P/S 304.4x
Dividend 0.0%
P/E -17.5x
Book Value ₹ 8.82
PEG Ratio 23.7x
ROE -58.8%
P/B 13.3x
Shareholding Pattern

Institutions
Rambabu Chirumamilla
1.56 %
Iepf
0.14 %
Promoters
Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)
60.0 %
Others
Increase    Decrease    No change
Company Profile Detailed

Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.
Investors (36)
Followers (7)